Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia
Phase 3 study to evaluate the efficacy and safety of dociparstat sodium in adults with newly diagnosed untreated acute myeloid leukemia (AML) with adverse or intermediate genetic risk.
Acute Myeloid Leukemia
DRUG: Dociparstat|OTHER: Control
Overall Survival, Overall survival was defined for all study participants through 5 years after randomization.

Overall survival was to be measured from the date of randomization to the date of death from any cause. Participants not known to have died at last follow-up contact were to be censored on the date they were last known to be alive.

Due to early termination, subjects did not complete long term follow-up and efficacy (including overall survival outcome) was not analyzed., Measured from randomization to date of death from any cause, up to 1 year.
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of dociparstat sodium in combination with standard intensive induction and consolidation chemotherapy for the treatment of newly-diagnosed acute myeloid leukemia (AML) patients.